EW News and Press, Edwards Lifesciences Corporation From 03/25/19

Quick Take Silk Road Medical ( SILK ) intends to raise $75 million in an IPO of its common stock, per an amended registration statement . The company sells a transcarotid artery stenting device in the U.S. SILK is growing rapidly in the U.S., has strong growth prospects internationally ...

Results from a Phase 3 clinical trial, PARTNER 3 , evaluating Edwards Lifesciences' ( EW +9.1% ) SAPIEN 3 mitral valve in patients with severe symptomatic aortic stenosis (narrowing of the aorta) showed its superiority to surgery. The data were presented at the American College of Card...

NEW ORLEANS , March 16, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the results of the randomized PARTNER 3 Trial demonstrated superi...

Healthcare derived demands Edwards Lifesciences Corporation ( EW ) provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. Some two dozen street research analysts see next year and 5-year EW stock price growth a...

Edwards Lifesciences (NYSE: EW ) has agreed to pay $35M for the exclusive rights to acquire Corvia Medical , the developer of a CE-Mark'd transcatheter device, called InterAtrial Shunt, designed to treat heart failure with preserved or mid-range ejection fraction via providing continuous ...

IRVINE, Calif. , March 11, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced two strategic transactions involving companies with structural heart dis...

Quick Take Silk Road Medical ( SILK ) intends to raise $86.25 million in an IPO of its common stock, according to an S-1 registration statement . The firm is commercializing a transcarotid artery stenting device in the United States. SILK is growing well and has significant growth oppor...

Introduction Edwards Lifesciences Corp. (EW) provides products used to treat heart disease and critical care monitoring. The company's products are available in the United States and internationally. Edwards Lifesciences has a solid history of earnings growth with a boost to earnings exp...

IRVINE, Calif. , Feb. 19, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the Edwards PASCAL transcatheter valve repair system has received CE...

Merger activity decreased last week with two new deals announced and five pending deals closing. Deal Statistics: New Deals: The acquisition of Ellie Mae (ELLI) by Thoma Bravo for $3.7 billion or $99.00 per share in cash. The acquisition of CAS Medical Systems (CASM) by Edwar...